Workflow
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
Globenewswire·2025-06-26 21:05

Core Points - Kane Biotech Inc. has completed the conversion of a $1 million unsecured demand loan from an insider into a 3% unsecured convertible debenture due on June 26, 2030 [1] - The closing of this transaction is subject to final approval from the TSX Venture Exchange [2] - At the Annual and Special Meeting of Shareholders, all resolutions were voted in favor with 98% or higher, including the election of three new board directors [3] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds, leading to serious clinical outcomes and high costs [4]